secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0001493152-23-042711
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts and grants Priority Review for Abeona's pz-cel BLA; PDUFA date May 25, 2024
--------------------------------------------------------------------------------

- FDA accepted BLA for pz-cel (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB) with Priority Review.
- PDUFA target action date set for May 25, 2024.
- FDA does not currently plan to hold an Advisory Committee meeting for pz-cel BLA.
- BLA supported by data from Phase 3 VIITAL study and Phase 1/2a study showing sustained wound healing and pain reduction.
- Priority Review grants eligibility for a Priority Review Voucher.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315223042711/0001493152-23-042711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315223042711/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-042711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer